| abstract |
REFERS TO COMPOUNDS OF FORMULA (I) WHERE X, U, L, T, M, A, Q, R1, R3, R4, R5, J, E AND G ARE AS DEFINED IN THE DESCRIPTION. PREFERRED COMPOUNDS ARE: (3aR, 7S, 10S, 11S, 12R, 24aR) -7-TERT-BUTYL-N - [(1R, 2R) -2- (DIFLUOROMETHYL) -1 - {[(1-METHYL CYCLOPROPYL) SULFONIL] CARBAMOIL} CYCLOPROPYL] -11-ETHYL-16-METOXY-5,8-DIOXO-1,2,3,3a, 5,6,7,8,11,12,20,21,22,23,24,24a -HEXADECAHYDRO-10H-9,12-METHANOCYCLOPENTA [18,19] [1,10,3,6] DIOXADIAZACICLONONADECINO [11,12-b] QUINOXALIN-10-CARBOXAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF THE HEPATITIS C VIRUS AND ARE USEFUL IN THE TREATMENT OF A HEPATITIS C VIRUS INFECTION |